Moderna has out-licensed a rare disease drug candidate to Recordati, accepting $50 million upfront for an asset that could ...
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David ...
Moderna will continue to lead clinical development and manufacturing for mRNA-3927Moderna to receive up to $160 million ...
In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...
As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...
Moderna's Chief Medical Officer Jacqueline Miller, who led the development of the company's mRNA-based COVID-19 vaccine ...
Moderna (MRNA) stock is in focus as the company annouces the departure of Jacqueline Miller its chief medical officer. Read ...
Moderna agreed to work with Recordati in a deal worth up to $160 million to advance development of a drug designed to treat the metabolic disorder propionic acidemia.
By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...
Moderna Inc.’s chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of ...
A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...
9don MSN
Why Moderna Stock Surged Today
The vaccine maker is expanding beyond its COVID-focused offerings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results